MedTrace Logo

A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma

NCT02099396 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-03-28

No results posted yet for this study

Summary

The purpose was to evaluate efficacy, safety and effects on survival for lobaplatin and Gemcitabine in combination with Docetaxel, which can provide a kind of completely new second-line chemotherapy program for osteosarcoma patients in aggressive-phase, provide accurate and reliable evidence-based results for clinical applications of lobaplatin in osteosarcoma patients as one of the third-generation of platinum drugs, and further consummate and enrich clinical practice guidance on osteosarcoma all over the world.

Conditions

  • Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma

Interventions

DRUG

Docetaxel+lobaplatin

DRUG

Gemcitabine+lobaplatin

Sponsors & Collaborators

  • China Association of Osteosarcoma Chemotherapy

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099396 on ClinicalTrials.gov